Thailand: Cryptocurrencies get major push as SEC approves first-ever ICO portal

Recently, Thailand’s SEC trimmed down the list of cryptocurrencies that could be used as an investment tool in the country’s ICO market and as base …

The Securities and Exchange Commission [SEC] of Thailand approved the country’s first ever Initial Coin Offering [ICO], capping off a wave of cryptocurrency adoption in the country.

As reported by a local news daily on 12 March, the Board of Directors of Thailand’s financial regulator gave a green light to the ICO portal. This decision will allow the portal to screen ICOs, conduct necessary background checks, confirm source codes, and ensure KYC norms are adhered to.

The Director of the Fintech Department at the SEC, Archari Suppiroj, said that the final approval of the ICO portal lay with the Thailand Commerce Ministry, and other relevant government agencies, an approval he deemed to be imminent.

Suppiroj added that the company that will operate the ICO portal is not registered in Thailand and is a foreign company. However, the Director did not mention any names in reference to the same, but stated that around eight companies were considered for the pre-consultation phase with the SEC to operate the portals.

She stated,

“The first ICO deal will be available for public offering in the near future under the digital asset royal decree.”

Coins and tokens are not on the same plateau, according to the country’s financial watchdog, with regulatory pressure still on the Security Token Offerings (STO). Suppiroj stated that STO introduction was prohibited as transactions relating to securities fell under a different law.

Suppiroj stated that the ICO market in Thailand saw a wave of improvement, from being project-based to being backed by actual assets. She added,

“In the future, the SEC will issue a criteria that allows companies to apply tokenisation to securities and other assets.”

In December 2018, the financial watchdog had announced plans to reduce the regulatory pressure surrounding ICOs. Tipsuda Thavaramara, the former General Secretary of the SEC called this proposition,

“An attempt to find greater equilibrium in the regulatory process and reduce regulatory impediments.”

Recently, Thailand’s SEC trimmed down the list of cryptocurrencies that could be used as an investment tool in the country’s ICO market and as base trading pairs. The existing list of currencies includes Bitcoin [BTC], Ethereum [ETH], and XRP, along with the country’s national currency, the Baht [TBH]. The SEC had booted out Litecoin [LTC], Bitcoin Cash [BCH] and Ethereum Classic [ETC] from its roster.


Subscribe to AMBCrypto’s Newsletter



Follow us on Telegram | Twitter | Facebook


Related Topics:CryptocurrencyICOnewsThailand

Related Posts:

  • No Related Posts

24/7 Market News: Better Green Technologies Could Help the ‘Green New Deal’

… are revolutionizing transportation, with a goal of making commutes a zero emissions event, and Elon Musk’s Boring Company may be headed to Las …

DENVER, CO / ACCESSWIRE / March 12, 2019 / The U.S. Government is already spending billions on climate change initiatives across the globe, but, if the “New Green Deal” becomes law, powering the US with 100% renewables could easily run into the trillions.

In fact, the American Action Forum estimates that the Green New Deal may cost $93 trillion over the next 10 years. However, will these trillions even make a difference with the climate and, other than squeezing taxpayers and companies, where will the money come from?

The world’s population is on pace to hit 8 billion people by 2023, so real innovation and technology are needed. Since most companies are reluctant to incorporate technologies that have significant adverse economic effects, the new green technologies must improve economic and energy efficiencies, in addition to being safer for the environment and the user.

It’s already happening, companies like Tesla and UBER are revolutionizing transportation, with a goal of making commutes a zero emissions event, and Elon Musk’s Boring Company may be headed to Las Vegas.

DowDuPont created an alliance with the U.S. Green Building Council, as well as dedicated an entire division to developing green and biodegradable products, ensuring that they are leading by example in creating a safer living environment for us all.

Blending improved economics and environmental benefits is a differentiator that Alltemp (OTC PINK: LTMP) is bring to the refrigerant industry. By producing a new coolant that is the safest on the market, but still able to reduce large corporations’ energy consumption, by 20%, or more. It’s being tested right now in multiple Fortune 500 facilities and it should soon begin to see market penetration.

Just switching to a floor wax that is cheaper, and more effective, will save Walmart $20 million in annual costs and reduced the amount of chemicals needed to buff the floors.

Even Amazon’s cloud is green and that’s just scratching the surface of its sustainability initiatives, as it aims to stem emissions from the millions of delivered packages each year.

Connect with 24/7 Market News on social media:

https://twitter.com/247MarketNewsHQ

https://www.facebook.com/247MarketNewsHQ/

About 24/7 Market News

As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN provides comprehensive corporate communications resources and tools to engage the investment community.

DISCLAIMER:

24/7 Market News (24/7MN) is a third party publisher and news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7MN’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.

The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable. 24/7MN makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. The editor of 24/7MN owns LTMP shares that can and will be sold. 24/7MN and/or its affiliates are not responsible for any gains or losses that result from the opinions expressed and are not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.

For further information on 24/7 Market News, please go to www.247marketnews.com

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan,” or “planned,” “will,” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 24/7MN undertakes no obligation to update such statements.

CONTACT:

24/7 Market News

Editor@247marketnews.com

SOURCE: 24/7 Market News

View source version on accesswire.com:

https://www.accesswire.com/538592/247-Market-News-Better-Green-Technologies-Could-Help-the-Green-New-Deal

Related Posts:

  • No Related Posts

CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of …

CymaBay sold 9,200,000 shares of its common stock in the offering, including 1,200,000 shares pursuant to the full exercise of the underwriters’ option …

NEWARK, Calif., March 11, 2019 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet need, today announced the closing of its previously announced underwritten public offering of its common stock. CymaBay sold 9,200,000 shares of its common stock in the offering, including 1,200,000 shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $12.50 per share before underwriting discounts and commissions. All of the shares of common stock were offered by CymaBay. CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar and for working capital and general corporate purposes.

Citigroup, Evercore ISI and Cantor Fitzgerald & Co. acted as the joint book-running managers for the offering. Oppenheimer & Co. Inc. and Roth Capital Partners acted as co-managers for the offering.

The securities described above were offered by CymaBay pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”). A final prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to this offering may be obtained from: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or telephone: 1-800-831-9146; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, New York, NY 10055, or by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; or Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About CymaBay

CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.

Cautionary Statements

This announcement contains forward-looking statements, including statements relating to CymaBay’s expectations regarding the anticipated use of proceeds and expectations and plans related to product development and clinical or regulatory events. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. CymaBay cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to the success, cost and timing of CymaBay’s product development activities, including clinical trials. Additional risks relating to CymaBay are contained in CymaBay’s filings with the SEC, including without limitation its Annual Report on Form 10-K and other documents subsequently filed with or furnished to the SEC, including the final prospectus supplement related to the offering dated March 5, 2019. CymaBay disclaims any obligation to update these forward-looking statements except as required by law.

Contacts:Hans VitzthumLifeSci Advisors, LLC(212) 915-2568Hans@LifeSciAdvisors.com

Related Posts:

  • No Related Posts

PAVmed Inc (PAVM) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. grew its stake in PAVmed Inc (NASDAQ:PAVM) by 289.4% during the 3rd quarter, according to its most recent Form 13F filing …

PAVmed logoVanguard Group Inc. grew its stake in PAVmed Inc (NASDAQ:PAVM) by 289.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 370,712 shares of the company’s stock after purchasing an additional 275,512 shares during the quarter. Vanguard Group Inc. owned approximately 1.40% of PAVmed worth $482,000 as of its most recent SEC filing.

Shares of PAVM stock traded up $0.07 on Friday, hitting $1.05. The company’s stock had a trading volume of 375,869 shares, compared to its average volume of 119,128. PAVmed Inc has a fifty-two week low of $0.86 and a fifty-two week high of $1.83. The company has a market capitalization of $28.50 million, a PE ratio of -2.02 and a beta of -0.03.

Separately, Maxim Group restated a “buy” rating and issued a $3.00 price target on shares of PAVmed in a research note on Monday, January 14th.

TRADEMARK VIOLATION WARNING: This report was first reported by Fairfield Current and is owned by of Fairfield Current. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.fairfieldcurrent.com/news/2019/03/10/pavmed-inc-pavm-shares-bought-by-vanguard-group-inc.html.

About PAVmed

PAVmed Inc operates as a medical device company in the United States. The company’s lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device.

Featured Article: What impact do institutional investors have on markets?

Want to see what other hedge funds are holding PAVM?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAVmed Inc (NASDAQ:PAVM).

Receive News & Ratings for PAVmed Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for PAVmed and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

The Alkaline Water Company Inc. Announces Proposed Public Offering of Common Stock

In addition, Alkaline intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in …

SCOTTSDALE, Ariz., March 07, 2019 (GLOBE NEWSWIRE) — The Alkaline Water Company Inc. (NASDAQ and TSXV: WTER) (“Alkaline” or the “Company”), a leading producer of premium bottled alkaline drinking water sold under the brand name Alkaline88®, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering in the United States and Canada. All of the securities in the offering are to be sold by Alkaline. In addition, Alkaline intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Alkaline intends to use the net proceeds from the offering for general corporate purposes, which may include reducing any outstanding indebtedness, increasing its working capital or capital expenditures.

Canaccord Genuity LLC is acting as the sole bookrunner for the offering.

The offering will only be made by means of written prospectuses and prospectus supplements that form part of Alkaline’s existing Canadian MJDS base shelf prospectus dated February 26, 2019, in Canada, and U.S. shelf registration statement on Form S-3 dated January 30, 2019, and declared effective by the Securities and Exchange Commission (the “SEC”) on February 15, 2019, in the United States. Preliminary prospectus supplements and the accompanying prospectuses will be filed with the securities regulatory authorities in the Provinces of British Columbia, Alberta, Manitoba, Ontario and Saskatchewan, pursuant to the Multijurisdictional Disclosure System, and with the Securities and Exchange Commission in the United States. Copies of these documents will be available on the Company’s profiles on the SEDAR website maintained by the Canadian Securities Administrators at www.sedar.com or the SEC’s website at www.sec.gov, as applicable. Alternatively, copies of the preliminary prospectus supplements and the accompanying prospectuses, when available, may also be obtained from Canaccord Genuity LLC, 99 High Street, Suite 1200, Boston, MA 02110, Attn: Equity Syndicate Department, by telephone at (617) 371-3900 or by e-mail at prospectus@canaccordgenuity.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About The Alkaline Water Company Inc.

The Alkaline Water Company Inc. is a leading producer of premium 8.8 pH balanced bottled alkaline drinking water enhanced with trace minerals and electrolytes sold under the brand name Alkaline88®. The product offers consumers the unique opportunity to purchase alkaline water in conveniently packaged 500-milliliter, 700-milliliter, 1-liter, 1.5-liter, 3-liter and 1-gallon sizes. With its innovative, state-of-the-art, proprietary electrolysis process, the Company produces healthy, all-natural and great-tasting alkaline water for a balanced lifestyle. Founded in 2012, the Company is headquartered in Scottsdale, Arizona, and focuses on national distribution and marketing for retail sale of Alkaline88®, one of the fastest growing premium bottled water brands on the market.

Forward-Looking Statements

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws (“forward-looking statements”). All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Such forward-looking statements include, among others, statements regarding the proposed offering of shares of common stock and the intended use of proceeds from the proposed offering. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

The reader is cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking statement. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Risks and uncertainties about the Company’s business are more fully discussed in the Company’s disclosure materials, including its preliminary prospectus supplements related to this offering/Periodic Reports on Form 8-K and Annual Report on Form 10-K filed with the SEC and the Canadian securities regulators and which can be obtained from either at www.sec.gov or www.sedar.com. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.

The Alkaline Water Company Inc.

James Gilmore

Investor Relations

480-656-2423

james@alkaline88.com

Richard A. Wright

President and CEO

480-656-2423

investors@thealkalinewaterco.com

Media

Jessica Starman

888-461-2233

jessica@elev8newmedia.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Related Posts:

  • No Related Posts